These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11349820)

  • 21. Contribution of humoral systems to the short-term variability of blood pressure after severe hemorrhage.
    Ponchon P; Elghozi JL
    Am J Physiol; 1997 Jul; 273(1 Pt 2):R58-69. PubMed ID: 9249533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antagonistic action of OPC-31260, a vasopressin V2 receptor antagonist, on [Arg8]vasopressin-induced vasoconstriction in isolated simian femoral arteries.
    Chiba S; Tsukada M
    Eur J Pharmacol; 1992 Oct; 221(2-3):393-5. PubMed ID: 1330628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats.
    Fujita H; Yoshiyama M; Takeuchi K; Omura T; Yamagishi H; Iwao H; Miura K; Yoshikawa J
    Jpn J Pharmacol; 1998 Oct; 78(2):229-32. PubMed ID: 9829627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
    Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M
    Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Johnston CI
    Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
    Grove L; Christensen P; Bie P
    Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
    Mimura Y; Ogura T; Yamauchi T; Otsuka F; Oishi T; Harada K; Hashimoto M; Ota Z
    Acta Med Okayama; 1995 Aug; 49(4):187-94. PubMed ID: 7502678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
    Ponchon P; Elghozi JL
    Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1203-7. PubMed ID: 8572874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic vasopressin antagonism in two-kidney, one-clip renovascular hypertension.
    Burrell LM; Risvanis J; Phillips PA; Naitoh M; Johnston CI
    Clin Exp Hypertens; 1997; 19(5-6):981-91. PubMed ID: 9247769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro macro- and microautoradiographic localization of V1 and V2 receptors in the rat kidney using OPC-21268 and OPC-31260.
    Mimura Y; Ogura T; Hayakawa N; Otsuka F; Hashimoto M; Yamauchi T; Makino H; Ogawa N
    Nephron; 1997; 76(3):331-6. PubMed ID: 9226235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Mondritzki T; Mai TA; Vogel J; Pook E; Wasnaire P; Schmeck C; Hüser J; Dinh W; Truebel H; Kolkhof P
    Eur J Heart Fail; 2021 May; 23(5):743-750. PubMed ID: 32946151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.
    Tsukada J; Tahara A; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Vascul Pharmacol; 2005 Jan; 42(2):47-55. PubMed ID: 15722249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of V2 vasopressin agonist and antagonists on blood pressure regulation in normotensive (WKY) and spontaneously hypertensive (SHR) rats.
    Budzikowski A; Lon S; Paczwa P; Szczepanska-Sadowska E
    J Auton Nerv Syst; 1992 Jun; 39(2):87-95. PubMed ID: 1430797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of central vasopressin receptors reduces the cardiovascular response to acute stress in freely moving rats.
    Stojicić S; Milutinović-Smiljanić S; Sarenac O; Milosavljević S; Paton JF; Murphy D; Japundzić-Zigon N
    Neuropharmacology; 2008 Apr; 54(5):824-36. PubMed ID: 18339407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model.
    Mondritzki T; Kolkhof P; Sabbah HN; Gheorghiade M; Fürstner C; Schmeck C; Siedentop H; Schaefer S; Truebel H
    Am J Ther; 2011 Jan; 18(1):31-7. PubMed ID: 21192248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
    Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular effects of centrally administered arachidonic acid in haemorrhage-induced hypotensive rats: investigation of a peripheral mechanism.
    Yalcin M; Aydin C
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):447-53. PubMed ID: 19702598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat.
    Tachikawa K; Yokoi H; Nagasaki H; Arima H; Murase T; Sugimura Y; Miura Y; Hirabayashi M; Oiso Y
    Am J Physiol Endocrinol Metab; 2003 Dec; 285(6):E1161-6. PubMed ID: 12915399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.